I don't think the focus is leaving Kevetrin at all. Some I think are so into day to day events they forget that this industry is not an overnight shift work gotta have it now field. IMO Brilacidin could be a fairly easy drug to market short term. And from what I've gathered was getting plenty of attention before it was shut down. The potential to get a partnership is what Leo sees imo, and that brings us more attention to branch out Kevetrin even more. The antibiotic field NEEDS help because so many drugs out there just aren't doing the trick anymore.
